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Abstract
Direct comparison of pyridine versus pyrimidine substituents on a small but diverse set of ligands 
indicates that the pyrimidine substitution has the potential to enhance affinity and/or functional 
activity at α6 subunit-containing neuronal nicotinic receptors (NNRs) and decrease activation of 
ganglionic nicotinic receptors, depending on the scaffold. The ramifications of this structure-
activity relationship are discussed in the context of the design of small molecules targeting 
smoking cessation.
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Smoking is a leading cause of premature mortality in developed countries.1 Smoking is also 
a difficult addiction to overcome, with an unaided relapse rate of approximately 80% within 
the first month of abstinence.2 Nicotine (1, Figure 1) is widely recognized as the agent 
responsible for mediating smoking addiction. Currently, several FDA-approved 
pharmacological options exist for treatment of nicotine addiction. These include nicotine 
replacement therapy bupropion, and the recently approved drug Chantix® (varenicline, 2). 
While not approved for use in the United States, cytisine (3), a natural product, has been 
used for many years as a smoking cessation aid in Eastern European countries.3 Dianicline 
(4) was a compound under advanced clinical investigation by Sanofi-aventis for smoking 
cessation,4 but was discontinued from clinical development in 2008.
Activation of mesolimbic dopaminergic neurons leads to dopamine release, initiating a 
physiological response that contributes to the reinforcing effects of nicotine.5 While nicotine 
can interact with several neuronal nicotinic receptor (NNR) subtypes in the mesolimbic and 
nigrostriatal pathway, including α4*, α6* (the asterisk denotes the presence of additional 
subunits and/or stoichiometries) and α7 receptors, convincing evidence shows that α4 
and/or β2 subunits are crucial in the reinforcing effects of nicotine.6 Cytisine (3)3, 
varenicline (2)7 and dianicline (4)4 all produce varying degrees of nicotinic acetylcholine 
receptor activation, particularly at the α4β2* subtype. Varenicline (2) apparently acts via 
simultaneous activation and antagonism of the α4β2* receptor.5 Elucidation of the exact 
mechanism is complicated by the fact that in addition to α4β2* activity, varenicline also 
interacts with α7 and α6β2* receptors.8 Compounding this complexity is the presence of an 
α4-β2 interface within a subset of the α6* receptors (i.e., the α6α4β3 but not the α6β2β3).
Recent data show that the α6β2* NNRs contribute to the effect of nicotine on dopamine 
release in the nucleus accumbens.9 These observations have led to questions regarding the 
role of α6β2 functional activity in mediating nicotine addiction.10 While previous work 
using subunit-null mutant mice has separately implicated the β2 and α4 subunits in the 
heteropentameric receptors involved in addiction, this paper reports on the relative 
contribution of α4β2* and α6β2* receptors in modulating mesolimbic and nigrostriatal 
dopamine release within a set of diverse compounds. Such data could guide discovery of a 
next-generation smoking cessation candidate with an optimum profile, perhaps overcoming 
the presently available therapies’ shortcomings, which include poor tolerability, complex 
titration schedule, and potential safety issues.11 While the pharmacological requirements for 
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binding to the α4β2* NNRs are reasonably well established, less is known about the 
structural requirements for ligand binding to and activation of α6β2* receptors.12 This 
dearth of understanding about the structure-activity relationship (SAR) for α6β2* ligands is 
additionally complicated by uncertainties about the precise subunit composition of α6β2* 
receptors in rodents and primates.13 The continued need for α6* -selective ligands with a 
range of functional activity for study in models of nicotine addiction as well as other disease 
states has motivated the initial α6β2* SAR report detailed herein.
During the initial screening of a diverse set of sixteen compounds selected from Targacept’s 
compound library, several hits with nanomolar to micromolar affinity at the α6β2* subtype 
were identified and subsequently profiled for functional activity. Among the compounds 
profiled were alkynylpyrrolidines 5a and 5b (Figure 2).14 In measurements of dopamine 
(DA) release, while the pyridine analog 5a possessed a modest level (42%) of efficacy with 
respect to α6* - mediated DA release, the pyrimidine analog 5b demonstrated a relative >3 
fold enhancement (Table 1)15
This initial observation led to the hypothesis that a pyrimidine substituent could confer 
α6β2* functional selectivity onto other scaffolds. Therefore, an additional set of pyridine 
and pyrimidine pairs were identified, synthesized20 and evaluated to complete a pyridine-
pyrimidine matrix on a small, structurally diverse set of scaffolds to evaluate this hypothesis.
The metanicotines 8a and 8b were prepared by Heck coupling of alkene 7 with 3-
bromopyridine or 5-bromopyrimidine according to a previously reported method (Scheme 
1).21
The preparation of quinuclidines 11a and 11b is illustrated in Scheme 2. Quinuclidinone 9 
was condensed under basic conditions with 3-pyridinecarboxaldehyde or 5-
pyrimidinecarboxaldehyde to give vinylquinuclidinones 10a or 10b. Hydrogenation under 
standard conditions afforded the saturated ketone intennediates, which were subjected to 
Wolff-Kishner conditions to give products 11a and 11b, respectively.
The readily available pyroglutamic acid 1222 was converted to alkene 14 by reduction, 
protecting group interconversion, Swem oxidation of the resulting alcohol 13 followed by 
olefmation (Scheme 3). Treatment of 14 with 3-bromopyridine or 5-bromopyrimidine under 
Heck conditions gave substituted vinylpyrrolidines 15a and 15b, respectively.
Preparation of both chiral and racemic forms of compound 20a (Scheme 4) has been 
previously reported.23 Application of this same methodology likewise afforded the desired 
pyrimidine analog 20b.
Compounds 23a and 23b were prepared according to similar procedures to those previously 
reported (Scheme 5).24
The collection of pyridine/pyrimidine compound pairs was first evaluated for binding 
affinity across several nicotinic receptor subtypes (Table 2). All of the compounds possessed 
high affinity at α4β2*. A slight drop in affinity for the pyrimidine analogs relative to the 
corresponding pyridines at the α4β2* subtype was noted for all except 23b. A much wider 
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range of affinities was observed for the α6β2* subtype, from nanomolar to micromolar 
binding; again, the pyrimidine analogs showed a trend toward slightly reduced affinity with 
the exception of 23b. In general, the compounds displayed selectivity for the α4β2* subtype 
relative to α6β2* and α7. Two noteworthy compounds are quinuclidine 20a, which 
possesses high affinity across all three subtypes, and 20b, wherein high affinity is retained 
for α4β2* andα6β2* while α7 affinity is diminished.
In functional measurements of dopamine release, the results for the metanicotine pair 8a/b 
are quite striking. While pyridine 8a is a full agonist at DA release mediated via the α4β2* 
receptor subtype (122%, 8.3 μM EC50), it has no functional activity at α6β2*. In contrast, 
pyrimidine 8b is a partial agonist (73%, 5.9 μM) at α4β2*-mediated dopamine release as 
well as via α6β2* (80% EMax), albeit with low potency (37 μM EC50). In the case of 
quinuclidines 11a/b, both are potent, full antagonists of both α4β2* and α6β2* -mediated 
dopamine release. For vinylpyrrolidine pair 15a/b, both analogs exhibited similar levels of 
efficacy and potency for both α4β2* and α6β2* -mediated dopamine release. We note that 
the relatively low α6β2* affinity of 15b (325 nM) still translates to good potency (530 nM 
EC50). Two possible explanations exist for this. First, α6β2* may be analogous to α4β2* 
wherein the Ki value reflects binding to desensitized state(s) and the EC50 value indicates 
binding to the functional state of the receptor. Perhaps for α6β2* these two states are more 
similar than for α4β2* Another possibility is that EC50 values in the complex α6β2* forms 
(eg α6α4β3β2) responsible for mediating dopamine release in the functional assay may 
reflect cooperativity of both a subunits and may therefore differ significantly from values 
expected for an α6β2* -containing receptor.
Quinuclidines 20a and 20b are intriguing compounds in that they possess relatively low 
efficacy but high potency at α4β2*-mediated dopamine release, while they are very potent 
full agonists at α6β2* -mediated dopamine release. We believe that this is the first report of 
full agonists with functional selectivity (both efficacy and potency) for the α6β2* subtype. 
Finally, tropinone derivatives 23a and 23b are both moderately potent partial agonists at 
α4β2*-mediated dopamine release. Both compounds also possess appreciable efficacy (50 
and 77%) and robust potency (200 and 100 nM, respectively) at α6β2* -mediated dopamine 
release.
A secondary, albeit extremely important goal in optimizing the pharmacological profile for 
smoking cessation was to improve functional selectivity for α6β2* vs, ganglionic receptor 
activation. Activation of the ganglionic α3β4* subtype may cause some of the side effects of 
nicotine and nicotinic ligands.25 Enhanced selectivity for central vs. peripheral sites, 
particularly with respect to the cardiovascular system, is therefore anticipated to improve 
tolerability in vivo. The compounds of this study were therefore evaluated for functional 
activity at the α3β4* subtype, and the functional potencies (ECT50s) compared with those 
for α4β2* and α6β2* activation to generate selectivity ratios (Table 3). Most compounds 
exhibited fairly high efficacy at α3β4*, with little difference between the pyridine and 
pyrimidine analogs or across the various chemotypes. The exceptions were the 
metanicotines 8a/b and the related vinylpyrrolidines 15a/b. Our current hypothesis is that 
the greater degree of flexibility of these scaffolds is less well tolerated in the α3β4* binding 
domain. Significant differences in potency occurred both between scaffolds and for 
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pyridines versus pyrimidines. Notably, for α4β2* moving from pyridine to pyrimidine 
generally increased EC50,s (decreased potency). Fairly wide variances in functional 
selectivity across the compound set were noted (0.4 to 127× for α3β4* vs. α4β2* and 0.26 
to 410x for α3β4* vs. α6β2* ). It may be asked whether the two scaffolds produce different 
cation-π interactions within the conserved aromatic box of the various subtypes investigated 
here.26 Exchanging pyrimidine for pyridine enhanced functional selectivity for α4β2*-
mediated dopamine release relative to ganglionic activation in half the cases; with respect to 
α6β2* -mediated dopamine release relative to ganglionic activation, the selectivity 
improvements were more modest (2–4x) but also more consistent.
In conclusion, we provide novel SAR data on affinity and function for a diverse group of 
nicotinic ligands in α6β2* containing NNR subtypes. Direct comparison of pyridine versus 
pyrimidine substituents on this set of scaffolds indicates that this substitution has the 
potential to enhance α6β2* affinity and/or functional activity and to decrease ganglionic 
activation, depending on the scaffold. Additionally, we have identified two scaffolds with 
functional selectivity for α6β2* (exemplified by compounds 20a/b and 23a/b). Both may 
serve as tools to explore the role of α6β2* receptors in various disease states and as leads for 
further optimization of α6β2* activity. The present scaffolds should be investigated with a 
larger and more diverse set of molecules to test the SAR conclusions around α6β2* affinity 
and function, and identify additional selective compounds. An α6β2* selective ligand may 
provide a valuable tool in a repertoire of therapies needed for drug addiction and movement 
disorders such as Parkinson’s and Huntington’s diseases. An appropriately labeled α6β2* 
selective molecule may also become a useful PET ligand.
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Figure 1. 
Nicotine and nicotinic ligands for smoking cessation.
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Figure 2. 
Alkynylpyrrolidines.
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Scheme 1. 
Reagents and conditions: (a) MeNH2, DMF, K2C03; (b) (B0C)2O, THF; (c) 3-
bromopyridine or 5-bromopyrimidine, Pd(OAc)2, P(o-tol)3. Et3N, CH3CN; (d) TFA.
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Scheme 2. 
Reagents and conditions: (a) 3-pyridine- or 5-pyrimidine-carboxaldehyde, KOH, MeOH; (b) 
Pd/C, H2, MeOH; (c) N2H4, KOH, ethylene glycol.
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Scheme 3. 
Reagents and conditions: (a) LiAlH4, THF; (b) Pd/C, H2; (c) (B0C)2O; (d) Swem Oxidation; 
(e) Ph3PCH3Br, nBuLi; (f) 3-bromopyridine or 5-bromopyrimidine, Pd(OAc)2, P(o-tolyl)3, 
NMP; (g) TFA.
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Scheme 4. 
Reagents and conditions: (a) benzophenone imine; (b) LDA, 4-
bromomethyltetrahydropyran; (c) HBr; (d) K2CO3, EtOH.
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Scheme 5. 
Reagents and conditions: (a) LDA, Tf2NPh; (b) pyridine-3-boronic acid or pyrimidine-5-
boronic acid, Pd(Ph3P)4, Li Cl, DME, Na2CO3.
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Table 1.
In-vitro profile of Compounds 5a and 5b at NNR subtypes.
# α4β2*
Ki
(nM)a
α7
Ki
(nM)b
α6β2*
Ki
(nM)c
α4β2*
DA
EMax
%d
α4β2*
DA
EC50
(uM)d
α6β2*
DA
EMax
%e
α6β2*
DA
EC50
(uM)e
5a 20 ± 3 733 ± 299 242 ± 43 120 ± 18 13 ± 9 42 ± 8 0.7 ± 0.3
5b 30 ± 8 5770 ± 1170 340 ± 144 64 ± 7 3.2 ± 1.5 134 ± 29 1.2 ± 1.4
a.
Measured by displacement of epibatidine in mouse cortex.16
b.
Measured using [125I]-bungarotoxin in mouse hippocampal membranes.17
c.
Measured using [125I]-α-Conotoxin Mil in mouse olfactory tubercles, striatum and superior colliculus.18
d.
Measured in striatal synaptosomes as α-conotoxin Mil-resistant DA release.19
e.
Measured in striatal synaptosomes as α-conotoxin Mil-sensitive DA release.20
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Table 2.
In-vitro profile of pyridine (a) / pyrimidine (b) pairs at NNR subtypes.
# α4β2*
Ki
(nM)a
α7
Ki15
(nM)b
α6β2*
Ki
(nM)c
α4β2*
DA
EMa
x%d
α4β2*
DA
EC50
(uM)d
α6β2*
DA
EMax
%g
α6β2*
DA
EC50
(uM)g
8a 25 ± 7 >10k 1550 ± 214 122 ± 26 8.3 ± 4.3 0 NA
8b 69 ± 19 >10k 1060 ± 370 73 ± 3 5.9 ± 1.0 80 ± 18 37 ±3
11a 16 ± 2 449 ± 161 85 ± 24 98 ± 11e 0.026 ±0.007f 96 ± 19e 0.85 ± 0.76f
11b 59 ± 21 2590 ± 430 115 ± 42 92 ± 5e 0.32 ± 0.06f 91 ± 8e 2.5 ± 1.1f
15a 11 ± 4 3160 ± 940 184 ± 57 109 ± 11 4.4 ± 1.9 66 ± 20 0.8 ± 1.0
15b 24 ± 3 >10k 325 ± 70 133 ± 18 19 ± 1 48 ± 13 0.53 ± 0.45
20a 0.5 ± 0.1 69 ± 10 1.1 ± 0.3 29 ± 2 0.034 ± 0.007 109 ± 14 0.007 ± 0.001
20b 1.8 ± 0.8 1100 ± 220 8 ± 4 43 ± 7 0.45 ± 0.50 104 ± 10 0.09 ± 0.05
23a 9.8 ± 3.0 2110 ± 400 55 ± 4 75 ± 14 3.4 ± 3.0 50 ± 7 0.2 ± 0.2
23b 1.2 ± 0.5 9100 ± 3170 17 ± 3 45 ± 4 1.8 ± 0.7 77 ±9 0.10 ± 0.08
a
Measured by displacement of epibatidine in mouse cortex.17
b.
Measured using [125I]-bungarotoxin in mouse hippocampal membranes.18
c
Measured using [125I]-α-Conotoxin Mil in mouse olfactory tubercles, striatum and superior colliculus.19
d.
Measured in striatal synaptosomes as conotoxin Mil-resistant DA release.20
eAntagonist IMax %.
f
Ki for inhibition
g.
Measured in striatal synaptosomes as α-conotoxin MII sensitive DA release.20
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Table 3.
Functional selectivity for pyridine-pyrimidine pairs.
# α3β4*
Emax
%a
α3β4*
EC50
uMa
Functional
Selectivity
α3ß4* / α4β2*
EC50 ratio
Functional
Selectivity
α3β4* / α6β2*
EC50 ratio
5a 81 ±7 5.6 ± 1.3 0.4 8
5b 74 ±3 34 ±3 10.6 28
8a 45 ±9 218 ± 81 26 NA
8b 4 ± 2 9.5 ±2.3 1.6 0.26
11a 99 ±2 3.3 ±0.1 127b 3.9b
11b 106 ±6 28 ±4 87.5b 11.2b
15a 58 ±4 16 ±3 3.6 20
15b 97 ± 13 161 ±48 8.5 304
20a 106 ± 13 0.4 ±0.2 11.8 57
20b 95 ± 1 2.4 ±0.05 5.3 26.7
23a 71 ±9 21 ±7 6.2 105
23b 35 ± 5 41 ± 12 22.7 410
a
Measured by ACh release in interpeduncular nucleus tissue.27
b
The ratios for 11a, 11b reflect EC50/Ki.
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